MYMD Pharmaceuticals(MYMD) - 2022 Q3 - Quarterly Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the quarterly period ended: September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File No. 001-36268 MyMD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) New Jersey 22-2983783 (State or other jurisdiction of incorporation) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15( ...